A Biomaterial Platform Built for Clinical Use

We use bacterial cellulose, a naturally produced polymer with a nanofibrillar structure that closely mimics soft tissue. Unlike plant-derived cellulose, it contains no lignin or hemicellulose, giving it exceptional purity and biocompatibility. Its three-dimensional fiber network provides a smooth blood-contacting surface and supports early tissue integration with minimal inflammatory response.

To ensure long-term stability in small diameters, we combine this biological surface with a nylon reinforcement layer, which provides controlled compliance, kink resistance and mechanical strength — without exposing synthetic material to blood.

Our bioreactor process grows each graft with precise control over inner diameter, wall structure and mechanical performance, enabling reproducible, off-the-shelf availability when suitable autologous conduits are limited.

Artifex’s technology aims to deliver a ready-to-use artificial blood vessel with broad clinical applicability.

For clinicians: This could enable faster procedures, more predictable outcomes, and fewer complications.
For patients: It may support quicker recovery and reduce the likelihood of repeat interventions.

For healthcare systems: It may improve efficiency, optimize resource use, and help reduce long-term costs.

Overall, the technology has the potential to make vascular procedures simpler, safer, and more durable.